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ABSTRACT
Objectives: High rates of antituberculosis treatment
discontinuation have been reported in some areas of
Africa. The aim of this study was to determine the rate,
time to and determinants of antituberculosis treatment
default in Yaounde.
Design: This was a retrospective cohort study based
on hospital registers. Tuberculosis treatment default or
antituberculosis treatment discontinuation was deﬁned
as any interruption of treatment for at least 2 months
following treatment initiation. Sociodemographic and
clinical predictors of treatment discontinuation were
investigated with the use of Cox regressions models.
Setting: This study was carried out in the tuberculosis
diagnosis and treatment centre at Yaounde Jamot
Hospital, which serves as a referral centre for
tuberculosis and respiratory diseases for the capital
city of Cameroon (Yaounde) and surrounding areas.
Participants: All (1688) patients started on
antituberculosis treatment at the centre between
January and December 2009 were enrolled. Outcome
measures were antituberculosis treatment default and
time to treatment default.
Results: Of the 1688 included patients, 337 (20%)
defaulted from treatment, 86 (5.1%) died, treatment
failed in 6 (0.4%) and 104 (6.2%) were transferred.
Therefore, treatment was successfully completed in
1154 (68.4%) patients. Median duration to treatment
discontinuation was 90 days (IQR 30e150), and 62%
of treatment discontinuation occurred during the
continuation phase. Hospitalisation during the
intensive phase (adjusted HR 0.69; 95% CI 0.54 to
0.89) and non-consenting for HIV screening (1.65;
1.24 to 2.21) were the main determinants of defaulting
from treatment in multivariable analysis.
Conclusions: The default incidence rate is relatively
high in this centre and treatment discontinuation
occurs frequently during the continuation phase of
treatment. Action is needed to improve adherence to
treatment when received on an ambulatory basis, to
clarify the association between HIV testing and
antituberculosis treatment default, and to identify other
potential determinants of treatment discontinuation in
this setting.
INTRODUCTION
Tuberculosis is endemic in the majority of
sub-Saharan African countries where the
highest global annual incidence rates are
recorded.
1 The expected therapeutic success
target of 85% among newly diagnosed indi-
viduals with positive smears is largely
unachieved in many settings in sub-Saharan
Africa.
1 Defaulting from tuberculosis treat-
ment is one of the reasons for this sub-
optimal performance. Tuberculosis treatment
default or antituberculosis treatment discon-
tinuation is deﬁned as any interruption of
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Open Access Researchantituberculosis treatment for at least 2 months following
treatment initiation.
23Antituberculosis treatment
discontinuation is associated with disease reoccurrence
following treatment, increased mortality, maintenance
of micro-organism reservoirs and emergence of drug-
resistant species of mycobacterium.
4
The directly observed treatment (DOT) strategy has
been recommended by the WHO
5 for improving the
outcome of care for tuberculosis. Implementation of the
DOT strategy started in Cameroon in the mid-1990s and
was expanded to the entire country in the year 2000.
Despite this, available evidence suggests that antituber-
culosis treatment discontinuation has remained rela-
tively high.
6 Many factors have been linked to
antituberculosis treatment discontinuation in sub-
Saharan Africa, including infrequent bacilloscopic
monitoring, transfer of patients across health service
units, lack of family support, side effects of medications,
healthcare system factors and patient misinformation.
7e9
In general, studies on the determinants of antitubercu-
losis treatment discontinuation in Africa and in
Cameroon are generally outdated and less reﬂective of
the DOT and highly active anti-retroviral therapy eras,
and the few relevant studies are heterogeneous.
78In
addition, none of the relevant studies were conducted in
Cameroon after DOT was implemented. In this context,
therefore, updated information is needed on antituber-
culosis treatment discontinuation and determinants that
reﬂects both the DOT era and recent improvements in
access to HIV testing and treatment, in order to guide
further improvement in the outcomes of care for
tuberculosis.
The aim of the current study was to assess the inci-
dence rate, determinants and time to antituberculosis
treatment discontinuation in the real-life setting of
a tuberculosis diagnosis and treatment centre in
Yaounde, Cameroon.
METHODS
Study setting
The study was conducted in the pneumology depart-
ment of Yaounde Jamot Hospital, which serves as
a referral centre for tuberculosis and respiratory diseases
for the capital city of Cameroon (Yaounde) and
surrounding areas. It is one of the major centres for the
diagnosis and treatment of tuberculosis in Cameroon.
The pneumology service of Yaounde Jamot Hospital has
257 beds and in 2009 managed 11% of all cases of
tuberculosis diagnosed in Cameroon. Approximately
1600e1800 patients with tuberculosis have been diag-
nosed and treated by the centre in the last 5 years.
Yaounde Jamot Hospital also hosts an approved treat-
ment centre that provides care to people living with HIV
infection. Patients registered at the tuberculosis treat-
ment centre from January to December 2009 were
considered for inclusion in the study. The study was
approved by the administrative authorities of Yaounde
Jamot Hospital.
Deﬁnition and classiﬁcation of tuberculosis cases
Patients who receive care at the centre for the diagnosis
and treatment of tuberculosis at Yaounde Jamot Hospital
are consecutively registered as they are started on treat-
ment. The approach is similar for patients with past
exposure to antituberculosis treatment: those patients
who report back to the centre with active tuberculosis
and who have been treated in the past for at least
1 month are registered again with a new number and
started on a standardised retreatment regimen. The
following international deﬁnitions are applied
2 35 : (1)
smear-positive pulmonary tuberculosis (PTB+): acid-fast
bacilli found in at least two sputum specimens; (2)
smear-negative pulmonary tuberculosis (PTB):
persisting negative ﬁndings on three sputum examina-
tions after a 10-day course of non-speciﬁc antibiotic
treatment in a patient with tuberculosis-like clinical and
radiological signs, and in the absence of any obvious
cause; (3) extra-pulmonary tuberculosis: tuberculosis
involving organs other than the lungs. Patients with past
exposure to antituberculosis treatment are usually smear
positive
2 and are further classiﬁed as ‘relapse’ (ie, reoc-
currence of the disease following a successful antituber-
culosis treatment course), ‘failure’ (ie, positive smear
after 5 months of antituberculosis treatment) and
‘treatment after default’ (ie, starting tuberculosis treat-
ment again after 2 consecutive months of interruption).
A ‘new case’ is a patient with tuberculosis who has never
been exposed to antituberculosis treatment for more
than 1 month in the past. ‘Other cases of tuberculosis’
refers to patients who do not ﬁt into one of the cate-
gories described above (ie, a patient relapsing for
a second time with tuberculosis, with the involved
mycobacterium being sensitive to antituberculosis
medication, and treated for 6 months with standard
regimens).
Detection and management of HIV infection
At the centre for the diagnosis and treatment of tuber-
culosis at Yaounde Jamot Hospital, all patients with
tuberculosis are screened for HIV infection free of
charge after informed consent has been obtained from
the patient or a relative for dependant patients. This
includes detection of anti-HIV 1 and anti-HIV 2 anti-
bodies in the serum with the use of two rapid tests: the
Determine HIV ½ test (Abbot Laboratories, Tokyo,
Japan) and the Immunocomb II HIV 1 and 2 Bispot kit
(Organics, Courbevoie, France). A patient is classiﬁed as
HIV positive when the two tests are positive. For discor-
dant tests, a conﬁrmatory Western blot test (New Lav
Blot; Sanoﬁ Diagnostics Pasteur, Chaska, Minnesota,
USA) is conducted. All HIV-positive patients are started
on prophylaxis with cotrimoxazole, while those with
a CD4 lymphocyte count <200/mm
3 (or <15% of the
total lymphocyte count in those <15 years of age) are
started on triple antiretroviral therapy free of charge.
Initial antiretroviral regimens consist of the combina-
tions lamivudineezidovudineeefavirenz or lamivudinee
stavudineeefavirenz.
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Tuberculosis treatment defaultTuberculosis treatment
Tuberculosis treatment at the centre is based on the DOT
approach, in accordance with the guidelines of the
Cameroon National Programme against Tuberculosis and
the WHO recommendations.
2 3 Patients are admitted
during the intensive phase of antituberculosis treatment
or are treated as outpatients. Antituberculosis drugs are
dispensed free of charge to all patients. Category I treat-
ment regimens are used for new patients and category II
regimens for retreatment cases. New cases are treated
with a regimen that includes an intensive 2-month phase
with rifampicin (R), isoniazid (H), ethambutol (E) and
pyrazinamide (Z), followed by a 4-month continuation
phase with rifampicin and isoniazid. During retreatment,
streptomycin (S) is added to category I medications (R,
H, E, Z). Therefore, retreatment cases are treated with
RHEZS for 2 months, followed by 1 month on RHEZ and
5 months on RHE. During the intensive phase, adherence
is directly monitored by the healthcare team for admitted
patients, and during weekly drug collection for outpa-
tients. The continuation phase is conducted on an
outpatient basis and adherence assessed during monthly
drug collection visits.
Monitoring and outcomes of tuberculosis treatment
During antituberculosis treatment, PTB+ patients are re-
examined for acid-fast bacilli at the end of months 2, 5
and 6 for new cases, and at the end of months 3, 5 and 8
in case of retreatment. PTB patients and those with
extra-pulmonary tuberculosis are monitored clinically
and/or radiologically at the same frequency. At the end
of treatment, patients are ranked into mutually exclusive
categories
2 as: (1) cured: the patient has a negative
smear in the last month of treatment and in least one of
the preceding months; (2) treatment completed: the
patient has completed the treatment but does not have
a smear result for the end of the last month; (3) failure:
the patient has at least two positive smears at the 5th
month or later during treatment; (4) death: death from
any cause during treatment; (5) defaulter: a patient
whose treatment has been interrupted for at least
2 consecutive months; and (6) transfer: the patient has
been transferred to complete treatment in another
centre and their treatment outcome is unknown.
Data collection
Data for the study were collected from the tuberculosis
treatment registers and antituberculosis treatment forms
of the tuberculosis treatment centre at Yaounde Jamot
Hospital. Data were collected on age, sex, residence
(urban vs rural), history of exposure to antituberculosis
treatment, site of tuberculosis infection, status for HIV
infection, CD4 lymphocyte count (in those with HIV
infection), intensive antituberculosis treatment setting
(hospital vs ambulatory), outcome of tuberculosis treat-
ment and time to treatment discontinuation. Cure and
tuberculosis treatment completion were considered
favourable outcomes (successful treatment) while death,
default and failure were considered unfavourable
outcomes.
10
Statistical methods
Data were analysed using SPSS V.12.0.1 for Windows
(SPSS) and SAS/STAT V.9.1 for Windows (SAS Insti-
tute). Results are presented as counts (proportions) and
medians (IQR). Group comparisons used the c
2 test and
equivalents for qualitative variables, and analysis of vari-
ance (ANOVA) and equivalents for quantitative vari-
ables. Cox proportional hazard regression models were
used to relate baseline characteristics to treatment
discontinuation during follow-up. Exploratory analyses
were adjusted for age and sex, and then all signiﬁcant
predictors identiﬁed (p<0.05) were entered into the
same multivariable model adjusted for sex and age. All
Cox models were stratiﬁed by type of patient (ie, new
patient, retreatment) to account for differences in the
duration of treatment. The KaplaneMeier estimator was
also used to depict the probability of treatment discon-
tinuation across strata of signiﬁcant predictors, and
group comparisons were made using the log-rank test. A
p value of <0.05 was considered statistically signiﬁcant.
RESULTS
Study population and antituberculosis treatment
discontinuation rate
Between January and December 2009, 1688 patients with
tuberculosis were registered at the centre for the diag-
nosis and treatment of tuberculosis. Their demographic
details, clinical proﬁles and outcomes are summarised in
table 1. Their median age was 32 years (IQR 25e42 years)
and 954 (56.5%) were men. There were 1231 (73%)
cases of PTB+, 168 (10%) of PTB and 289 (17%) of
extra-pulmonary tuberculosis. The cumulative incidence
rate of antituberculosis treatment discontinuation was
20% and the treatment success rate was 68.4%.
Time to tuberculosis treatment discontinuation
Antituberculosis treatment interruption in 210 patients
(62.3%) occurred during the continuation phase of
treatment (ﬁgure 1) and the median (IQR) time to
tuberculosis treatment discontinuation was 90 days
(30e150). Tuberculosis treatment discontinuation was
more likely to occur during the continuation phase in
those hospitalised during the intensive phase than in
those treated as outpatients (134 (74.9%) vs 77 (48.7%);
p<0.0001).
Determinants of treatment discontinuation
The probability of treatment discontinuation according
to intensive treatment setting and whether an HIV test
had been carried out is shown in ﬁgure 2. At each time
point during follow-up, the probability of treatment
discontinuation was always lower in patients hospitalised
during the intensive treatment phase than in those
treated as outpatients during the intensive phase. Simi-
larly, the probability of discontinuation was always lower
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Tuberculosis treatment defaultin patients with known status for HIV infection than in
those with unknown status.
Cox regression models were used to examine predic-
tors of treatment discontinuation using the observed
follow-up period for all participants in the cohort. In
models adjusted for age and sex, hospitalisation during
the intensive phase reduced the risk of treatment
discontinuation (HR 0.58; 95% CI 0.46 to 0.72), while
having PTB (1.59; 1.15 to 2.21) or unknown status for
HIV infection (1.28; 1.17 to 1.41) signiﬁcantly increased
the risk of treatment discontinuation. Following further
adjustment for those variables that were signiﬁcant in
basic models, ambulatory treatment during the intensive
phase and unknown status for HIV infection were the
main determinants of antituberculosis treatment
discontinuation (table 2).
DISCUSSION
In this study, we have assessed the incidence of antitu-
berculosis treatment discontinuation and predictors of
treatment discontinuation in a large cohort of patients
treated for tuberculosis in a major referral centre in
Cameroon. The treatment success rate was 68.4% and
the cumulative incidence of treatment discontinuation
was 20% overall and 19.4% among patients with smear-
positive pulmonary tuberculosis. Discontinuation was
most likely to occur during the continuation phase of
treatment and mostly among those treated as outpatients
during the intensive phase and among patients with
unknown status for HIV infection.
Treatment discontinuation in our study was based on
the WHO’s deﬁnition, which characterises a defaulter as
a patient whose treatment has been discontinued for at
least 2 consecutive months.
2 Compared with the few
other studies from Africa that have used similar deﬁni-
tions, the discontinuation rate in our cohort was similar
to that reported by Shargie et al in South Ethiopia,
11
lower that that found by Kaona and colleagues in
Zambia,
12 and higher than that reported by Tekle et al in
Arsi in Ethiopia.
13 These studies, however, differ from
our study in a number of respects. The largest of the
studies had 20% fewer patients than our cohort,
13 while
the other two had less than a quarter of the number of
participants in our sample.
11 12 Furthermore, the two
studies in Ethiopia involved only rural participants, with
one based only on patients with smear-positive tubercu-
losis,
13 while the study in Zambia was based on a cross-
sectional sample of urban dwellers.
12 In general, it has
been recognised that using a stricter deﬁnition for
treatment discontinuation results in much higher rates
than when using the WHO deﬁnition.
7
Before reorganisation of the struggle against tubercu-
losis in Cameroon and implementation of the DOT
strategy, the antituberculosis treatment discontinuation
rate was 31.7% among adults with PTB+ in Yaounde
Jamot Hospital.
14 Our study suggests that the DOT
strategy has impacted positively on antituberculosis
treatment discontinuation, with a 12% drop in the
discontinuation rate, although much effort is still
needed to bring the rate below 10%. The currently
observed discontinuation rates are twice as high as the
expected rate of <10%, a requirement if the 85% anti-
tuberculosis treatment success rates prescribed in the
Millennium Development Goals are to be achieved.
15
Treatment discontinuation is a major challenge for
programmes against tuberculosis, in that non-adherence
to antituberculosis treatment is associated with reo-
ccurrence of the disease, preservation of reservoirs for
Figure 1 Time to treatment discontinuation.
Figure 2 Duration of follow-up for treatment discontinuation
(days).
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Tuberculosis treatment defaultmicro-organism dissemination, emergence of drug
resistant species of mycobacterium and increased
tuberculosis related deaths.
16
Two out of three patients who defaulted from treat-
ment in our study did so during the continuation phase
of tuberculosis treatment. Predominantly late antitu-
berculosis treatment discontinuation (ie, after the
intensive phase) has also been conﬁrmed in a systematic
review.
17 This late discontinuation may partly be
explained by the improved condition of the patient
following the intensive phase of treatment. It is possible
that patients who feel clinically better following this
phase are less motivated to continue treatment as they
do not feel the need to do so.
16
Tuberculosis treatment on an outpatient basis during
the intensive phase and unknown status for HIV were
the main determinants of treatment discontinuation
found in our study. This suggests that direct daily
supervision reduces the risk of drop out. This could be
explained, at least in part, by the fact that those who
receive antituberculosis treatment as inpatients during
the intensive phase also receive more education about
the disease, its duration and the outcome of care and are
therefore more motivated to continue treatment for the
required duration. Two studies from Zambia and
Ethiopia have reported that poor knowledge of antitu-
berculosis treatment duration among patients was asso-
ciated with a high risk of treatment discontinuation.
12 13
Unlike our results, however, another study in Spain
found no protective effect of DOT on antituberculosis
treatment discontinuation.
18 Patients with unknown
status for HIV in our study were more likely to be those
who did not consent for the test, since cost is not
a constraint for HIV screening in our setting. It is
possible that faced with the persisting invitation from
healthcare personnel to accept HIV screening, some of
the non-consenting patients would prefer to stop the
antituberculosis treatment and walk away from the
programme. The stigmatisation of people living with
HIV is a reason for not consenting for screening.
19 20 We
also speculate that antituberculosis treatment discon-
tinuation is not the direct consequence of not
consenting for HIV screening, but that the latter is just
an indicator of the proﬁle of those patients who will
adhere less to any medical prescription. The effects of
non-consenting for HIV screening on antituberculosis
treatment discontinuation have not been investigated by
other studies.
7 In agreement with a previous study in
Cameroon,
14 and unlike ﬁndings from elsewhere,
11 age,
gender and living in a rural area were not associated with
antituberculosis treatment discontinuation in our study.
This study used administrative data routinely collected
for monitoring the national programme against tuber-
culosis. Because such data collection is not comprehen-
sive, we were unable to investigate the effects of some
potential determinants of antituberculosis treatment
discontinuation, such as the patient’s knowledge about
tuberculosis, the distance from the patient’s residence to
the tuberculosis centre, the side effects of antitubercu-
losis treatment and chronic alcohol abuse.
8 92 1 e23 That
no systematic effort was in place to trace patients who
interrupted their treatment during the year of the study
has probably introduced some biases into our ranking of
patients according to the outcome of care. For instance,
some patients who died in-between drug collection visits
would have been inappropriately classiﬁed as defaulters,
particularly among HIV infected patients.
24e26 Our study
also has major strengths including the large population
and inclusion of forms of tuberculosis common in this
setting. Unlike recent studies on this topic in Africa,
assessment of predictors of treatment discontinuation
used robust methods to account both for the observed
time to treatment discontinuation as well as for differ-
ences in the duration of treatment for various forms of
tuberculosis.
7 The recent studies have either been based
on patients with HIV and tuberculosis, or lacked infor-
mation on status for HIV. Accordingly, none investigated
the effects of HIV testing on the outcome of care for
tuberculosis, as done successfully in this study.
In conclusion, antituberculosis treatment discontinu-
ation in this setting is relatively high, and tends to occur
more during the continuation phase of treatment.
Patients who receive treatment on an outpatient basis
during the intensive phase and those who do not
Table 2 HRs and 95% CIs for predictors of antituberculosis treatment discontinuation from Cox regression analysis
Characteristics
Basic models Final models
HR (95% CI) p Value HR (95% CI) p Value
Age (per year) 1.01 (1.00 to 1.01) 0.121 1.01 (1.00 to 1.01) 0.133
Sex (women vs men) 0.96 (0.77 to 1.20) 0.723 0.99 (0.79 to 1.23) 0.922
Hospitalised intensive phase 0.58 (0.46 to 0.72) <0.0001 0.69 (0.54 to 0.89) 0.004
Residence (urban vs rural) 0.92 (0.67 to 1.26) 0.596 ee
Clinical form of tuberculosis
Positive smear (reference) 1.00 (reference) 1.00 (reference)
Negative smear 1.59 (1.15 to 2.21) 0.005 1.25 (0.89 to 1.76) 0.192
Extra-pulmonary 0.99 (0.73 to 1.34) 0.948 0.96 (0.71 to 1.30) 0.780
Unknown status for HIV 1.28 (1.17 to 1.41) <0.0001 1.65 (1.24 to 2.21) 0.0007
Basic models are adjusted for age and sex, and ﬁnal models are further adjusted for all signiﬁcant predictors in the basic models.
All Cox models are stratiﬁed by type of patient (ie, new patient, retreatment) to account for differences in the duration of treatment.
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Tuberculosis treatment defaultconsent for HIV screening are more likely to interrupt
their antituberculosis treatment. Speciﬁc actions
targeting these subgroups would likely improve the
outcomes of care for tuberculosis in this centre. That
patients treated entirely on an ambulatory basis were less
like to achieve good outcomes of care as compared to
those hospitalised during the intensive treatment phase,
together with the much higher discontinuation rates in
the same setting in the pre-DOT era, all suggest that the
DOT strategy is associated with improved outcomes of
care for tuberculosis in this setting. Prospective studies
are needed to investigate other determinants of antitu-
berculosis treatment discontinuation and reﬁne the
incidence data based on a more objective ascertainment
of the outcomes of care.
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